p38α MAPK, a key therapeutic target in HNSCC can be considered as a prognostic marker and is implicated in
response to radiation-therapy (RT). We compared the outcome of treatment viz. RT (group-I) and concurrent-RT (combination
of RT with chemotherapy or surgery, group-II) with respect to p38α MAPK in HNSCC. The case-controlled study
was performed on 143 HNSCC patients. From these p38α estimation was done thrice only for 104 patients (52 each in
group-I and II), at pre, during and post-therapy periods using surface Plasmon resonance (SPR) technology, ELISA and
western blot analysis. In HNSCC the over-expressed p38α levels declined after treatments in both the groups. The patients
receiving only RT had a lower p38α level than those treated with concurrent-RT (p=0.009). Hence, p38α was found to be
responsive to RT in HNSCC and it may be useful in predicting the treatment outcome and further improve the prognosis
of disease in addition to clinical parameters.
Keywords: p38α, HNSCC, radiation therapy, chemotherapy, surgery.
Rights & PermissionsPrintExport